Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Phase III Boost For Esperion But Does It Own Its Destiny?

Executive Summary

Esperion will be allowed to enroll patients on high dose statins into the Phase III pivotal trial of its cholesterol lowering drug bempedoic acid, but with competing products ahead in the race, the product faces an uphill battle for market share even if it does garner approval.

Advertisement

Related Content

Still Hope For Zetia Expansion After Negative Committee
Panel: Approve, but limit Amgen PCSK9; payers have final say
US advisers endorse PCSK9 Praluent, but limited population

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register